Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer
Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer
默克公司的Keytruda作為腎癌的輔助治療顯示更好的無病生存率
- Merck & Co Inc (NYSE: MRK) has announced interim data from Phase 3 KEYNOTE-564 trial evaluating Keytruda as a potential adjuvant treatment of renal cell carcinoma (RCC) following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.
- Based on an interim analysis conducted by an independent Data Monitoring Committee, Keytruda monotherapy demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo.
- The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies.
- Merck will present the results at an upcoming medical meeting and submit them to regulatory authorities.
- Keytruda is currently approved in the U.S., Europe, and Japan combined with axitinib for the first-line treatment of patients with advanced RCC.
- Price Action: MRK shares are up 0.37% at $76.4 in premarket trading on the last check Thursday.
- Merck & Co Inc (NYSE: MRK) has announced interim data from Phase 3 KEYNOTE-564 trial evaluating Keytruda as a potential adjuvant treatment of renal cell carcinoma (RCC) following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.
- Based on an interim analysis conducted by an independent Data Monitoring Committee, Keytruda monotherapy demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo.
- The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies.
- Merck will present the results at an upcoming medical meeting and submit them to regulatory authorities.
- Keytruda is currently approved in the U.S., Europe, and Japan combined with axitinib for the first-line treatment of patients with advanced RCC.
- Price Action: MRK shares are up 0.37% at $76.4 in premarket trading on the last check Thursday.
- 默克公司(Merck&Co Inc.)亞洲網加利福尼亞州聖何塞2月18日電(紐約證券交易所市場代碼:MRK)公佈了第3階段Keytrnote-564試驗的中期數據,該試驗評估Keytruda作為腎切除(腎臟手術切除)或腎切除和轉移病灶切除後的腎細胞癌(RCC)的潛在輔助治療。
- 根據一個獨立的數據監測委員會進行的中期分析,Keytruda單一療法與安慰劑相比,在DFS方面顯示出統計上顯著的和臨牀上有意義的改善。
- 該試驗將繼續評估總存活率(OS),這是一個關鍵的次要終點。KEYTRUDA在本試驗中的安全性情況與先前報道的研究中觀察到的情況一致。
- 默克公司將在即將召開的醫療會議上公佈結果,並提交給監管機構。
- Keytruda目前在美國、歐洲和日本被批准與Axitinib聯合用於晚期腎癌患者的一線治療。
- 價格行動:在週四最後一張支票的盤前交易中,Mr k股價上漲0.37%,至76.4美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!